secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001193125-23-266722
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA eligible for $5M milestone from FDA acceptance of Day One's NDA for tovorafenib in pediatric glioma
--------------------------------------------------------------------------------

- FDA accepted Day One Biopharmaceuticals' NDA for tovorafenib as monotherapy for relapsed/progressive pediatric low-grade glioma.
- XOMA now eligible for a $5 million milestone payment from Day One under the tovorafenib royalty purchase agreement.
- XOMA originally acquired up to $54M in milestones and mid-single digit royalties on tovorafenib from Viracta in March 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312523266722/0001193125-23-266722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312523266722/d569726d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-266722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer